News

/News

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment

2020-06-29T14:35:04+00:00

Our dynamic systematic benefit-risk analysis of antiviral drug combination lopinavir-ritonavir for COVID-19 patients has just been published. Our research team found there was no clear benefit for the use of lopinavir-ritonavir compared to standard of care in severe COVID-19. This semi-quantitative analysis used the Benefit-Risk Action Team (BRAT) framework. The exposure of interest was lopinavir-ritonavir treatment in severe COVID-19 compared to standard of care, placebo or other treatments. In comparison to standard of care, data for several key benefts and risks were identifed for lopinavir-ritonavir. Risk data suggested a possible decrease in serious adverse events. There was a reduction in acute [...]

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment2020-06-29T14:35:04+00:00

New consortium to monitor safety and effectiveness of COVID-19 vaccines

2020-06-22T09:40:04+00:00

A new consortium to monitor the safety and effectiveness of COVID-19 vaccines has been formed by the Drug Safety Research Unit and MEMO Research, University of Dundee.   Developers of vaccines are required to demonstrate quality, safety and efficacy for their products before members of the public start receiving them. Therefore it is necessary to conduct post marketing observational studies to monitor the safety and effectiveness of COVID-19 vaccines to fill any gaps in knowledge obtained from premarketing clinical trials. It is important that these studies report in real-time any safety or lack of effectiveness signals so that action can be [...]

New consortium to monitor safety and effectiveness of COVID-19 vaccines2020-06-22T09:40:04+00:00

First systematic benefit-risk assessment of Remdesivir published

2020-05-29T11:09:37+00:00

Remdesivir for COVID-19 patients is ‘favourable’ says first systematic benefit-risk study We have just published the first ever systematic benefit-risk analysis of antiviral drug remdesivir for COVID-19 patients. The analysis found a ‘favourable’ profile overall, though there is currently limited safety data available. The study was published on 28th May in the journal, Drug Safety, and recorded all possible benefits and risks for COVID-19 patients receiving remdesivir obtained by evaluating public data from peer reviewed journals and some pre-publication clinical trial data. We found benefits of remdesivir including quicker recovery time, with one study showing median recovery time for remdesivir patients [...]

First systematic benefit-risk assessment of Remdesivir published2020-05-29T11:09:37+00:00

Hospital PASS studies: conducting real-world observational studies in secondary care

2020-06-05T10:13:24+00:00

Our article in the Spring edition of Pharmafile explains our unique SCEM method for conducting PASS studies in hospitals and specialist care in the context of rivaroxaban. The DSRU developed a unique methodology to conduct Post-authorisation Safety Studies (PASS) in hospitals and specialist care in the UK, known as Specialist Cohort Event Monitoring (SCEM) in 2010 (see reference below). This technique was developed to address the need for safety studies in secondary care, specifically for patients who receive initial or all drug treatment in hospitals or hospital outpatient clinics. This method is ideally suited to conducting PASS studies on Direct Oral Anticoagulants, [...]

Hospital PASS studies: conducting real-world observational studies in secondary care2020-06-05T10:13:24+00:00

The need for active surveillance of the safety and effectiveness of COVID-19 vaccines

2020-06-22T09:55:45+00:00

by Saad Shakir (First published as a BMJ Rapid Response on 12th May 2020) A key component of efforts to control COVID-19 will be an effective vaccine. There are many potential COVID-19 vaccines in preclinical development and clinical trials around the world. History has shown that the benefits far outweigh risks for vaccines of infectious diseases. The normal vaccine development process including clinical trials may take 10 - 15 years. To address urgent public health need, such as the COVID-19 pandemic, the vaccine development process can be dramatically shortened to as little as 12-18 months, including testing and release. To protect [...]

The need for active surveillance of the safety and effectiveness of COVID-19 vaccines2020-06-22T09:55:45+00:00

COVID-19: DSRU’s latest research and capabilities update

2020-05-29T16:57:56+00:00

The DSRU team is heavily engaged in conducting studies related to the COVID-19 pandemic. Dozens of clinical trials are underway around the world, many on repurposed drugs, but it is important to look at the benefit-risk balance of the proposed new treatments. Inevitably clinical trials on these products will be shortened, so it will be essential to monitor the effectiveness of these new treatments at the post-marketing stage. Our preparations to provide near real-time intensive monitoring of new COVID-19 vaccines are well underway and we are in touch with stakeholders in order to form a consortium. This builds on our experience [...]

COVID-19: DSRU’s latest research and capabilities update2020-05-29T16:57:56+00:00

Business As Usual at the DSRU

2020-04-30T10:51:29+00:00

The DSRU team is used to working remotely while maintaining high standards and completing studies on time. We have the connectivity to enable us to remain open for business, conducting our current work and accepting new business as usual. We welcome enquiries about potential new studies and projects and will continue to handle them in the usual way, including discussing your requirements with you online, by email or phone. Please do not hesitate to contact us.  

Business As Usual at the DSRU2020-04-30T10:51:29+00:00

Cytokine Storm: A major killer in patients with severe COVID-19 infection.

2020-04-06T14:14:28+00:00

  Professor Saad Shakir writes: What are Cytokines? Cytokines are a group of proteins that are secreted by cells in the immune system.  They act as chemical messengers to regulate other immune cells.  Cytokines are released from one immune cell to affect the actions of another cell in the immune system by binding to receptors on its surface. Cytokines include interferons, interleukins, lymphokines and tumour necrosis factors. Cells which release cytokines include macrophages, lymphocytes (both B and T lymphocytes) and other immune cells. Cytokines exert their effects in tissues locally or circulate in the blood and lymph. The difference between cytokines [...]

Cytokine Storm: A major killer in patients with severe COVID-19 infection.2020-04-06T14:14:28+00:00

Article: The need for evolution in pharmacovigilance

2020-03-30T16:31:47+00:00

Pharmafocus published an interview with our Director, Saad Shakir, in its March issue, focusing on the need for pharmacovigilance to evolve in order to handle the challenges posed by scientific innovation and political upheaval. While we have seen a shift to more proactive pharmacovigilance, we will need further modification of existing methods, especially for biologic therapies where patients tend to be sicker, taking many medicines and suffering concurrent illnesses. Read the article in full here: https://en.calameo.com/read/0061133857c3d689fd31b?page=16

Article: The need for evolution in pharmacovigilance2020-03-30T16:31:47+00:00

Systematic Benefit-Risk Assessment published

2020-02-26T15:28:00+00:00

Benefit-risk assessment is used to weigh up the benefits of a specific treatment with the risks of that treatment. The DSRU team has just published a report on a systematic benefit-risk assessment conducted to compare the benefits and risks of a new mode of delivery of an existing drug with that of the well-established tablet/ film formulation. This key publication explains how a semi-quantitative benefit-risk method is used to support risk management. The paper, “Systematic benefit-risk assessment for buprenorphine implant: a semi-quantitative method to support risk management”, reports on a benefit-risk assessment conducted by the DSRU to determine whether a new [...]

Systematic Benefit-Risk Assessment published2020-02-26T15:28:00+00:00

Contact Info

Drug Safety Research Unit Bursledon Hall, Blundell Lane, Southampton, SO31 1AA, U.K.

Phone: +44 (0)23 80 40 86 00

Recent Posts